
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is projected to have a positive future with its wide product portfolio and potential for growth, alongside its potential for revenue of $332M and a 1.4x EV/Sales multiple in 2027. While facing challenges in its wound care segment due to reimbursement changes, the company's high number of Medicare patients with chronic/acute wounds provides a strong market. Additionally, the company's leadership and financials, despite setbacks in clinical trials and challenges for some treatments, make it a promising investment opportunity.
Bears say
Organogenesis Holdings is facing significant challenges in its skin substitute segment, which accounts for a majority of its product offerings. CMS reimbursement changes, which went into effect in 2026, have led to a significant decline in the market and have negatively impacted the company's financials. While the potential FDA approval of ReNu could unlock a multibillion-dollar market opportunity, the clinical data on this product has been mixed and it is uncertain if it will receive adequate coding, coverage, and commercialization. The company's financials and valuation will likely continue to be under pressure until the CMS headwinds are resolved and the company successfully navigates through this uncertain period.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares